Omeros Corporation (OMER)
NASDAQ: OMER · Real-Time Price · USD
13.72
+0.20 (1.44%)
Apr 24, 2026, 12:04 PM EDT - Market open
Omeros Employees
Omeros had 175 employees as of December 31, 2025. The number of employees decreased by 27 or -13.37% compared to the previous year.
Employees
175
Change (1Y)
-27
Growth (1Y)
-13.37%
Revenue / Employee
n/a
Profits / Employee
-$19,143
Market Cap
987.43M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 175 | -27 | -13.37% |
| Dec 31, 2024 | 202 | 4 | 2.02% |
| Dec 31, 2023 | 198 | 2 | 1.02% |
| Dec 31, 2022 | 196 | -17 | -7.98% |
| Dec 31, 2021 | 213 | -64 | -23.10% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,300 |
| Maravai LifeSciences Holdings | 435 |
| MeiraGTx Holdings | 403 |
| KalVista Pharmaceuticals | 275 |
| Xencor | 260 |
| Geron | 258 |
| Janux Therapeutics | 109 |
| Annexon | 96 |
OMER News
- 8 days ago - CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug) - Business Wire
- 23 days ago - Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results - Business Wire
- 4 weeks ago - Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026 - Business Wire
- 4 weeks ago - Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment - Business Wire
- 2 months ago - Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program - Business Wire
- 3 months ago - Omeros Announces First Commercial Sales of YARTEMLEA® - Business Wire
- 3 months ago - Omeros prices transplant complication drug at $36,000 per dose - Reuters
- 4 months ago - Omeros Announces New Date for YARTEMLEA® Approval Conference Call - Business Wire